Key facts
- This page summarizes BOEHRINGER INGELHEIM INTERNATIONAL GMBH's Form 3 filing for Minerva Neurosciences, Inc. (NERV).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Jul 2023, 16:15.
BOEHRINGER INGELHEIM INTERNATIONAL GMBH - 27 Jun 2023 Form 3 Insider Report for Minerva Neurosciences, Inc. (NERV)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- NERV
- Reported as of
- 27 Jun 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/ Christoph Gauger, Registered Manager (Prokurist), the GP, /s/ Martin Bergmann, Registered Manager (Prokurist), the GP
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
BOEHRINGER INGELHEIM INTERNATIONAL GMBH filed Form 3 for Minerva Neurosciences, Inc. (NERV) on 07 Jul 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NERV
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,275,000
- Date
- 27 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NERV
holding
Derivative
Pre-Funded Warrant (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 27 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 225,225
- Exercise price
- $0.0100
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The securities are held directly by Boehringer Ingelheim International GmbH ("International GmbH"), a wholly owned indirect subsidiary of C. H. Boehringer Sohn AG & Co. KG ("Parent"). Boehringer AG (the "GP") is the General Partner of Parent. Under Securities and Exchange Commission rules and regulations, the GP may be deemed to have indirect beneficial ownership of the shares held by International GmbH.
Footnote F2
The Pre-Funded Warrant will not expire until exercised in full.